Evoke Pharma Enters Agreement with Rho CRO to Submit NDA
Evoke Pharma, Inc.-a pharma company focused on treatments for gastrointestinal diseases-announced an agreement with Rho, Inc.-a regulatory consulting and contract research organization (CRO).
Rho and Evoke will collaborate with the preparation and submission of Evoke's planned 505(b)(2) New Drug Application (NDA) for Gimoti™-the company’s nasal delivery formulation of metoclopramide, which helps relieve symptoms associated with acute and recurrent diabetic gastroparesis in adult women.
Read the full release here.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
